ArticleJournal of Alzheimer's disease : JAD2021
Why Inclusion Matters for Alzheimer's Disease Biomarker Discovery in Plasma.
Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Novel set of plasma proteins classifies Alzheimer's dementia in African American individuals with high accuracy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- LC-MS/MS proteomics identifies plasma proteins related to cognition over 9-year follow-up.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Comprehensive Overview of Bottom-Up Proteomics Using Mass Spectrometry.ACS measurement science au · 2024Review
- Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease.Alzheimer's research & therapy · 2024Article
- Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression.medRxiv : the preprint server for health sciences · 2024Article
- Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease.Research square · 2024Article
- A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer's disease across ethnic groups.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Article
- Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort.Neurology · 2023Article
- Quantification of race/ethnicity representation in Alzheimer's disease neuroimaging research in the USA: a systematic review.Communications medicine · 2023Review
- Increased Amino Acid Absorption Mediated byJournal of microbiology and biotechnology · 2023Article
- Advances, obstacles, and opportunities for machine learning in proteomics.Cell reports. Physical science · 2022Article
- Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
- Prognosis of Alzheimer's Disease Using Quantitative Mass Spectrometry of Human Blood Plasma Proteins and Machine Learning.International journal of molecular sciences · 2022Article
- Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans.EBioMedicine · 2022Article
- Exposing the Brain Proteomic Signatures of Alzheimer's Disease in Diverse Racial Groups: Leveraging Multiple Data Sets and Machine Learning.Journal of proteome research · 2022Article
- Targeted Lipidomics To Measure Phospholipids and Sphingomyelins in Plasma: A Pilot Study To Understand the Impact of Race/Ethnicity in Alzheimer's Disease.Analytical chemistry · 2022Article
- What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer's Disease Biomarker Research? A Qualitative Vignette Analysis.Journal of Alzheimer's disease : JAD · 2022Article
- Characterizing Plasma Biomarkers of Alzheimer's in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort.Frontiers in neurology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
backgroundAfrican American/Black adults have a disproportionate incidence of Alzheimer's disease (AD) and are underrepresented in biomarker discovery efforts.
objectiveThis study aimed to identify potential diagnostic biomarkers for AD using a combination of proteomics and machine learning approaches in a cohort that included African American/Black adults.
methodsWe conducted a discovery-based plasma proteomics study on plasma samples (N = 113) obtained from clinically diagnosed AD and cognitively normal adults that were self-reported African American/Black or non-Hispanic White. Sets of differentially-expressed proteins were then classified using a support vector machine (SVM) to identify biomarker candidates.
resultsIn total, 740 proteins were identified of which, 25 differentially-expressed proteins in AD came from comparisons within a single racial and ethnic background group. Six proteins were differentially-expressed in AD regardless of racial and ethnic background. Supervised classification by SVM yielded an area under the curve (AUC) of 0.91 and accuracy of 86%for differentiating AD in samples from non-Hispanic White adults when trained with differentially-expressed proteins unique to that group. However, the same model yielded an AUC of 0.49 and accuracy of 47%for differentiating AD in samples from African American/Black adults. Other covariates such as age, APOE4 status, sex, and years of education were found to improve the model mostly in the samples from non-Hispanic White adults for classifying AD.
conclusionThese results demonstrate the importance of study designs in AD biomarker discovery, which must include diverse racial and ethnic groups such as African American/Black adults to develop effective biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.